A Phase 1 interventional study of Comparator: fluticasone and Placebo in Asthma, sponsored by Merck Sharp & Dohme LLC. Completed. Open to participants aged 18 Years to 55 Years. Per ClinicalTrials.gov, last updated 2015-05-05.
Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 147 studies testing fluticasone in Asthma — 1 open to participants now, 4 under way, 2 of them phase 3. Fluticasone · Asthma.
Among the 147 studies testing fluticasone in Asthma, this one is the 135th largest by enrollment of the 146 interventional ones that give a count, is one of 5 that started in 2008, is one of 22 in phase 1, and was the 49th registered.
4,850 studies on the registry are indexed under Asthma; 604 are open to participants now.
Browse Asthma studies →1 of the 147 studies testing fluticasone in Asthma is open now, in 1 country. Recruiting first, the newest first:
University of Wisconsin, Madison · Sites in United States
Ages 18+ · Healthy volunteers
By country, each count listing its studies:
Fluticasone: first FDA approval 1990 (CUTIVATE), first EMA approval 2008. What it is approved for, and how studies give it, is on its page →
Of the 415 Asthma studies recruiting now, 140 (34%) set no upper age limit and 204 (49%) stop at 75 or younger; 145 take children under 18; 105 take healthy volunteers.
This study: 18 Years to 55 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
147 studies; the count open now beside each. This study's row is marked.
First in 1999; this study’s year is marked. 5 started in 2008.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 13 is below the median of 79 across 3,346 interventional studies indexed under Asthma.
Median enrollment 100 across the 146 interventional studies. Of the 130 that completed or were terminated, 68 (52%) have results posted.
This tab as a report to print or save as PDF → With an account.
107 of 147 have an industry lead sponsor. The 10 most frequent:
This study is registered under Merck Sharp & Dohme LLC, one of the names counted as Merck & Co., Inc. Under that name alone:
Merck Sharp & Dohme LLC is the lead sponsor of 2,167 studies on the registry; 132 are open to participants now.
Of its 504 completed or terminated interventional studies of FDA-regulated products, 371 (74%) have results posted.
23 studies in Asthma by Merck & Co., Inc: none open now, none under way, none of them phase 3. Of 21 finished, 13 (62%) have results posted.
Among the 23 studies in Asthma by Merck & Co., Inc, this one is the 18th largest by enrollment, is one of 7 that started in 2008, is one of 10 in phase 1, and was the 5th registered.
Merck & Co., Inc’s Asthma studies by the year they started, since 2002.
2 of the studies testing fluticasone in Asthma that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT05757102Phase 3GlaxoSmithKlineA Study to Compare the Efficacy, Safety and Tolerability of FF/UMEC/VI With FF/VI in 12-17-year-olds With Asthma | 2027-01-26 |
| NCT07664527University of Wisconsin, MadisonNovel Method for Removal of Orally Deposited Inhaled Fluticasone Propionate | 2027-09 |
Add all 2 to your calendar (.ics) → With an account.
Among the 147 studies testing fluticasone in Asthma, from their registry updates:
Among Merck & Co., Inc’s 23 in Asthma:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The primary goals of this study will be to implement innovative processing and detection assays to qualify induced sputum measurements of markers of allergen-induced airway inflammation. The results of this study are intended to form a platform to be used in the clinical development of novel asthma therapeutics.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
study medication + Pbo
Drug: Comparator: fluticasone · Drug: Placebo
Pbo + study medication
Drug: Comparator: fluticasone · Drug: Placebo
Two puffs, of 250 µg each, will be administered to each patient to obtain a 500-µg dose at each prespecified time point. A total of five (5) doses (500 µg) each of inhaled fluticasone will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
Also known as: fluticasone
Two puffs, of placebo, will be administered to each patient at each prespecified time point. A total of five (5) doses of placebo will be administered during the single blind run-in phase. and matching placebo will be administered in a 3-day period during Periods 1 and 2. Dosing will be twice a day for 3 days, ending after the morning dose on the third day.
Hour 24 Fold Change From Period Baseline in Interleukin-5 (IL-5) Protein Concentration (pg/mL)
Time frame: Baseline and 24 hours post allergen challenge
Hour 24 Fold Change From Period Baseline in Interleukin-13 (IL-13) Protein Concentration (pg/mL)
Time frame: Baseline and 24 hours post allergen challenge
First Patient Entered: 28-Jan-2008 Last Patient, Last Visit: 05-Mar-2009 1 site
| Milestone | Placebo Then Fluticasone | Fluticasone Then Placebo |
|---|---|---|
| Started | 6 | 7 |
| Completed | 6 | 7 |
| Not completed | 0 | 0 |
| Milestone | Placebo Then Fluticasone | Fluticasone Then Placebo |
|---|---|---|
| Started | 6 | 7 |
| Completed | 6 | 7 |
| Not completed | 0 | 0 |
| pg/mL | Placebo | Fluticasone |
|---|---|---|
| Hour 24 Fold Change From Period Baseline in Interleukin-5 (IL-5) Protein Concentration (pg/mL) | 2.57 (1.37 to 4.84) | 0.87 (0.46 to 1.64) |
| pg/mL | Placebo | Fluticasone |
|---|---|---|
| Hour 24 Fold Change From Period Baseline in Interleukin-13 (IL-13) Protein Concentration (pg/mL) | 2.11 (1.41 to 3.17) | 0.85 (0.57 to 1.28) |
Collected over Adverse experiences were collected from the time the consent is signed through the 14 day follow up period after all treatment periods were completed. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Placebo | — | 0/13 (0%) | 5/13 (38.5%) |
| Fluticasone | — | 0/13 (0%) | 6/13 (46.2%) |
| Event | Placebo | Fluticasone |
|---|---|---|
| FatigueGeneral disorders | 1/13 | 2/13 |
| HeadacheNervous system disorders | 2/13 | 2/13 |
| NasopharyngitisInfections and infestations | 1/13 | 0/13 |
| RhinitisInfections and infestations | 1/13 | 0/13 |
| Urinary Tract InfectionInfections and infestations | 1/13 | 0/13 |
| Muscle Contractions InvoluntaryNervous system disorders | 1/13 | 1/13 |
| AsthmaRespiratory, thoracic and mediastinal disorders | 0/13 | 1/13 |
| CoughRespiratory, thoracic and mediastinal disorders | 0/13 | 1/13 |
| Oropharyngeal PainRespiratory, thoracic and mediastinal disorders | 0/13 | 1/13 |
| Rhinitis AllergicRespiratory, thoracic and mediastinal disorders | 0/13 | 1/13 |
| Age, Continuous(years) | All Patients |
|---|---|
| Mean | 25.9 (21 to 43) |
| Sex: Female, Male(Participants) | All Patients |
|---|---|
| Female | 9 |
| Male | 4 |
No study locations are listed for this record.
The record gives a start of Jan 2008, a primary completion of Feb 2009 and a completion of Mar 2009. It does not say whether these dates are actual or estimated.
Results were first posted in Jun 2010, 1 year 4 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Apr 2015. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Fluticasone